Literature DB >> 10211419

Neopterin serum levels in pancreatic adenocarcinoma.

G Manes1, O A Spada, P G Rabitti, B Feola, S Misso, A Minerva, G Uomo.   

Abstract

CONCLUSIONS: Activation of the immune system in pancreatic cancer is demonstrated by increased serum levels of neopterin, soluble Interleukin 2 receptor (sIL-2R), and Interleukin 6 (IL-6). Determination of these parameters does not provide benefit in the diagnosis of pancreatic cancer.
BACKGROUND: The aim of the study was to define the diagnostic value of serum neopterin, an in vivo marker of macrophage activity, in pancreatic cancer.
METHODS: Thirty-four patients with pancreatic cancer were studied. According to the UICC TNM classification 6 were in stage I, 9 in stage II, 6 in stage III, and 13 in stage IV. Twenty-four patients with chronic pancreatitis, 72 healthy blood donors, and 20 patients with jaundice resulting from gallstones were used as control groups. Neopterin, tumor necrosis factor (TNF), sIL-2R, and IL-6 were measured in serum in the different groups; Ca 19-9 was also measured in cancer and pancreatitis.
RESULTS: Serum levels of neopterin, sIL-2R, and IL-6 were higher in cancer than in pancreatitis and healthy donors, and in pancreatitis higher than in donors. Serum TNF was similar in the three groups. Serum levels of neopterin, TNF, sIL-2R, and IL-6 were not related to the tumor stage or to Ca 19-9 levels. A positive correlation was found between sIL-2R and neopterin levels. Neopterin levels in obstructive jaundice were similar to those of pancreatitis. Ca 19-9 at the recommended cutoff of 37 U/mL showed the best sensitivity and specificity (88.2 and 87.5%, respectively). At the selected cutoff neopterin, TNF, sIL-2R, and IL-6 showed low sensitivity and specificity in differentiating cancer from pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211419     DOI: 10.1385/IJGC:25:1:31

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  16 in total

Review 1.  Neopterin in clinical practice.

Authors:  M M Müller; H C Curtius; M Herold; C H Huber
Journal:  Clin Chim Acta       Date:  1991-09-14       Impact factor: 3.786

2.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present.

Authors:  E R Werner; G Werner-Felmayer; D Fuchs; A Hausen; G Reibnegger; J J Yim; W Pfleiderer; H Wachter
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

4.  Clinical significance of neopterin for prognosis and follow-up in ovarian cancer.

Authors:  G Reibnegger; H Hetzel; D Fuchs; L C Fuith; A Hausen; E R Werner; H Wachter
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

5.  A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.

Authors:  P Lissoni; F Brivio; L Fumagalli; C Galimberti; M Cataldo; M T Marsili; O Brivio; S Barni; G Tancini; A Angelini
Journal:  J Biol Regul Homeost Agents       Date:  1994 Jan-Mar       Impact factor: 1.711

6.  Serum levels of neopterin as related to the prognosis of human prostatic carcinoma.

Authors:  A Lewenhaupt; P Ekman; P Eneroth; A Eriksson; B Nilsson; L Nordström
Journal:  Eur Urol       Date:  1986       Impact factor: 20.096

7.  Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.

Authors:  G J Reibnegger; A H Bichler; O Dapunt; D N Fuchs; L C Fuith; A Hausen; H M Hetzel; H Lutz; E R Werner; H Wachter
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

9.  Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis.

Authors:  R Pezzilli; P Billi; E Beltrandi; R Mancini; M Casadei-Maldini; R Casadei; V M Greco; O Campione; M Miglioli
Journal:  Ital J Gastroenterol       Date:  1994-04

10.  Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

Authors:  C Haglund; P J Roberts; P Kuusela; T M Scheinin; O Mäkelä; H Jalanko
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

View more
  4 in total

Review 1.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.

Authors:  Si-Biao Su; Shan-Yu Qin; Wen Chen; Wei Luo; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

3.  Gamma interferon is dispensable for neopterin production in vivo.

Authors:  R Sghiri; J Feinberg; F Thabet; K Dellagi; J Boukadida; A Ben Abdelaziz; J L Casanova; M R Barbouche
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

4.  Biomarkers of Chronic Pancreatitis: A systematic literature review.

Authors:  Zobeida Cruz-Monserrate; Kristyn Gumpper; Valentina Pita; Phil A Hart; Christopher Forsmark; David C Whitcomb; Dhiraj Yadav; Richard T Waldron; Stephen Pandol; Hanno Steen; Vincent Anani; Natasha Kanwar; Santhi Swaroop Vege; Savi Appana; Liang Li; Jose Serrano; Jo Ann S Rinaudo; Mark Topazian; Darwin L Conwell
Journal:  Pancreatology       Date:  2021-01-22       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.